PPD Discovery Signs Technology Agreement With InforMax
Gains Access to GenoMax Enterprise Bioinformatics System
PPD Discovery, a wholly owned drug discovery subsidiary of PPD, Inc. (Nasdaq: PPDI), announced today a technology access agreement with InforMax, Inc. (Nasdaq: INMX) to use the GenoMax(TM) enterprise bioinformatics system. Under the terms of the agreement, PPD Discovery will gain broad access from InforMax to its proprietary bioinformatics system to manage and analyze massive quantities of genomic data resulting from PPD's functional genomics research program. PPD Discovery uses its proprietary functional genomics platform, the GSX(TM) system, to isolate functional inhibitors of any gene responsible for a selectable cellular property. This technology provides a direct approach to identify and validate novel therapeutic targets based on their functional role in a disease pathway and represents a powerful tool for functional genome annotation. Incorporating the GenoMax enterprise bioinformatics system will facilitate the management, analysis and mining of Expression and gene function data. "The modular structure of the GenoMax bioinformatics system integrates well with our functional genomics platform," said Tanya Holzmayer, Ph.D., co- inventor of the GSX System and vice president of genomics at PPD Discovery. "Applying this high throughput system of genomic data analysis, we expect to further expedite our identification and validation of novel targets."
Other news from the department business & finance
